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Background 
• Economic evaluation has been used as a strategic tool in the 
justification of harm reduction programmes in a politically difficult 
environment.  
• Many studies indicate that broad societal benefits outweigh low 
implementation costs even when more expensive AIDS and hepatitis 
C treatments are considered.  
• We carried out a systematic review to assess international evidence 
generated from these studies and the underlying quality in reporting 
and methods. This paper reports on the findings of the review of the 
costing methodologies.  
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Methods 
• Peer reviewed and grey literature was searched for studies published 
in English from 1990 until 2011.  
• Search terms included ‘cost’ or ‘economic’ and ‘substance abuse’ or 
‘injecting drug use*’ or ‘methadone’ or ‘substitution therapy’ or 
‘needle exchange’.  
• Cost analyses or economic evaluations were selected.  
• Information was collected on author, year of costing, currency, 
country, intervention, analysis type, perspective, outcomes, data 
sources, and main results.  
• Study methods were critiqued using the BMJ check list for economic 
evaluations and a quality score was developed.  
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RESULTS 
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Number of papers 
identified  
973 
 
Papers selected for 
abstract review 
116 
 
Papers included in 
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19 papers identified 
in grey literature 
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44 did not meet 
inclusion criteria 
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Location of studies 
Red >10 
Dark orange 6 - 10 
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BMJ check list review 
• 13% (9/71) scored greater than 90% on the BMJ check list 
• 32/71 scored greater than 80% 
• Most frequent problems in reporting were: 
– Lack of details on price adjustments (34) 
– Resource quantities not reported separately (30) 
– Perspective not clearly stated (28) (or justified – 61) 
– No justification for discount rate (26) 
– Economic importance not stated (25) 
– No justification for form of evaluation (22) 
– Currency and price data not recorded (21) 
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BMJ check list review – 
LMIC studies only 
• 27% (3/11) scored greater than 90% on the BMJ check list 
• 5/11 scored greater than 80% 
• Most frequent problems in reporting were: 
– Resource quantities not reported separately (7) 
– No justification for discount rate (7) 
– Details of the meta analysis not given (5) * 
– Lack of details on price adjustments (5) 
– Major outcomes not presented in disaggregated and aggregated way (5)* 
– Economic importance not stated (4) 
– Unit cost estimation methods not clear (4) * 
– Currency and price data not recorded (4) 
– Perspective not clearly stated (3) (or justified – 9) 
 
 * Not identified as frequent problem in HIC 
studies 
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Studies by region (>80% score on check 
list) n=32 – where has our evidence 
gone? 
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Costing methods – 
data 
• Primary cost data collection was used in 54% of the studies.  
• 18 studies used a bottom approach to costing – 2 of which used 
secondary cost data.  
• Fifty-three studies used a provider perspective, 12 used a societal 
one.  
• Ten studies used financial costing (including claims data and financial 
operating costs) and only 15 studies explicitly stated which type of 
costs were used 
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Costing methods - 
design 
Costing method Number of studies 
Micro-costing 
Utilisation survey plus cost data 10 (14%) 
Utilisation (best practice) plus national prices 1 (1%) 
Utilisation survey plus national prices 3 (4%) 
Utilisation survey plus secondary costs 2 (3%) 
National costing scheme 5 (7%) 
Programme costing 13 (18%) 
Financial costing (accounts/ payer/ budget) 10 (14%) 
Secondary cost data 21 (30%) 
Insufficient information on sources 6 (8%) 
HIV Modelling & Economics 
Type of costing by 
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The role of modelling in cost 
estimation  
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Cost model 
• Significant role of 
modelling (1/3 studies 
model costs) 
• 3 of which used primary 
data 
• Modelling requires good 
data..... 
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What role 
guidelines? 
• U.S has been at forefront of developing costing tools – DATCAP, 
SASCAP 
– Not used extensively:  overall - 5/71; for U.S. - 4/ 34 
• UNAIDS and ADB have intervention specific guidelines 
– Not used in HICs 
– 4/11 studies in LMICs use UNAIDS or ADB guidelines 
– 1 uses U.S. tool 
• Nor are generic tools such as BMJ checklist used extensively 
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Conclusions 
• Harm reduction economic evaluations are focussed in U.S. – studies 
from Europe and LMICs are limited 
• Economic evaluations are increasingly being published in LMICs  (see 
e-poster: Harker and Guinness). 
• BMJ check list provides information on the quality of reporting only 
but this is important if information to be used in further analyses 
• It is possible to produce good quality evidence from LMICs 
• Concern that guidelines are not being utilised 
• As journal editors, peer reviewers, authors and researchers we have 
responsibility to improve the evidence base 
 
